This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright.
Exhibit 2 Company Milestones
1996 Merger of Ciba-Geigy and Sandoz to create one of the largest healthcare companies
2002 Novartis Institutes for Biomedical Research (NIBR) is created, headquartered in the United States
2003 Acquisition of Mead Johnson & Co., a subsidiary of Bristol-Myers Squibb
2004 Novartis submits Xolair for EU approval for treatment of allergic asthma
NIBR announces joint project with the Broad Institute of MIT and Harvard to research type 2 diabetes
2005 Landmark trial on Gleevec/Glivec, to treat chronic myeloid leukemia, shows 90% of patients still alive after four years of treatment
Aclasta gains EU regulation approval for treatment of Paget’s bone disease
Acquired North American over the counter brand portfolio of Bristol-Myers Squibb, expanding Novartis’ presence
2006 Strategic biomedical R&D center opens in Shanghai
Novartis Institute for Tropical Disease (NITD) initiates research on malaria. Through partnership with World Health Organization (WHO), provides anti-malarial Coartem, for no charge in developing nations
Omnitrope receives European Commission approval; 1st product approved under the EU’s new regulatory pathway for follow-on biological products
2007 Completed non-core divestments of the Gerber and Medical Nutrition Business units to Nestlé for $5.5 billion and $2.5 billion, respectively
Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey
2008 Novartis announced an agreement to acquire 25% interest in Alcon, Inc., world leader in eye care with pharmaceutical, surgical, and consumer products (majority ownership acquired in 2010 and 100% in 2011)
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING TERM PAPERS TODAY AND GET AN AMAZING DISCOUNT
